Connor Quinn

Statistics

Publications

Citations

388

H-Index

Active since

1981

Affiliations

Arvinas (United States)(Current)

Connor Quinn is an author at Arvinas (United States) specializing in targeted protein degradation, medicinal chemistry, and proteasome-mediated degradation.

ORCID

Publications per year

1981–2024

Publications

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

Jennifer Cantley, Xiaofen Ye, Emma Rousseau et al. · Nature Communications · 2022 · 129 citations · Full text

Pharmacy, Molecular Biology, Oncology +14

Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules

Christopher M. Hickey, Katherine M. Digianantonio, Kurt Zimmermann et al. · Nature Structural & Molecular Biology · 2024 · 58 citations

Life Sciences, Biochemistry, Molecular Biology +11

PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models

Michael Berlin, Jennifer Cantley, Mark Bookbinder et al. · Journal of Medicinal Chemistry · 2024 · 30 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +6

Human--rat muscle somatic cell hybrids form myotubes and express human muscle gene products.

Connor Quinn, Peter N. Goodfellow, S. Povey et al. · Proceedings of the National Academy of Sciences · 1981 · 11 citations · Full text

Life Sciences, Cell Biology, Genetics +17

1–5 of 5